

PRECEPTORSHIP PROGRAMME

Brain Tumours

**ESMO
PRECEPTORSHIP**

**LUGANO SWITZERLAND
23-24 JUNE 2022**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:

Giuseppe Minniti, Italy

Michael Weller, Switzerland

ESMO PRECEPTORSHIP PROGRAMME

BRAIN TUMOURS

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Lugano, Switzerland
23-24 June 2022

CO-CHAIRS: Giuseppe Minniti, Italy
Michael Weller, Switzerland

SPEAKERS: Carmen Balaña, Spain
Dieta Brandsma, Netherlands
Enrico Franceschi, Italy
Emilie Le Rhun, Switzerland
Evangelia Razis, Greece

LEARNING OBJECTIVES

- To learn about the evidence base for diagnostic imaging, molecular pathology, and neurocognitive assessment in brain tumour patients
- To understand the basis of multi-modality treatment of lower and higher-grade gliomas
- To learn about local and systemic treatment options for meningiomas
- To learn about the multi-modality management of brain metastasis patients including targeted therapies in patients with actionable driver mutations and with novel immunotherapies
- To learn about future developments in the management of gliomas, meningiomas, brain metastases, and leptomeningeal carcinomatosis

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Thursday, 23 June 2022

09:00-09:15 15'	Opening and welcome	
15'	Welcome and introduction	Giuseppe Minniti, IT
09:15-10:30 75'	Session 1 Diagnostic challenges of Brain tumours	Chair: Evangelia Razis, GR
25'	Imaging for diagnosis and follow-up	Giuseppe Minniti, IT
25'	Brain tumour classification and molecular pathology	Michael Weller, CH
25'	Neurocognitive assessment and patient-reported outcomes	Dieta Brandsma, NL
10:30-11:00	Coffee break	
11:00-12:30 90'	Session 2 IDH-wild type Gliomas	Chair: Emilie Le Rhun, CH
2x15'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Carmen Balaña, ES
25'	Future developments	Michael Weller, CH
10'	Discussion	Faculty
12:30-13:30	Lunch	
13:30-15:00 90'	Session 3 IDH-mutant Gliomas	Chair: Michael Weller, CH
2x15'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Enrico Franceschi, IT
25'	Future developments	Michael Weller, CH
10'	Discussion	Faculty
15:00-15:30	Coffee break	
15:30-17:00 90'	Session 4 Meningioma	Chair: Enrico Franceschi, IT
2x15'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Giuseppe Minniti, IT
25'	Future developments	Evangelia Razis, GR
10'	Discussion	Faculty
19:30	Dinner	

Friday, 24 June 2022

09:00-10:30 90'	Session 5 Brain metastasis	Chair: Carmen Balaña, ES
2x15'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Dieta Brandsma, NL
25'	Future developments	Emilie Le Rhun, CH
10'	Discussion	Faculty
10:30-11:00	Coffee break	
11:00-12:30 90'	Session 6 Leptomeningial Carcinomatosis	Chair: Dieta Brandsma, NL
2x15'	2 x Participants clinical case discussion	Faculty
25'	Standards of care	Emilie Le Rhun, CH
25'	Future developments	Evangelia Razis, GR
10'	Discussion	Faculty
12:30-12:40 10'	Closing remarks and farewell	Giuseppe Minniti, IT Michael Weller, CH
12:40-13:40	Lunch	

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion